Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

mitted to continuing to invest in this promising technology and to bring it to market as soon as possible."

The ABSORB trial reinforces Abbott's commitment to research and develop innovative devices in vascular care. Abbott's robust vascular research program includes clinical trials in peripheral artery disease, carotid artery disease, and coronary artery disease. Key products in the vascular pipeline include: the Omnilink Elite(TM) Peripheral Stent System; the EMBOSHIELD NAV6(TM) Embolic Protection System for carotid stenting; and the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, which builds upon the proven performance of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System.

Onmilink Elite, EMBOSHIELD NAV6 and XIENCE PRIME are investigational devices and are not available for sale.

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 110 patients in Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days; six, nine, 12 and 18 months; and two years, with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug eluting stent, including successful deployment of the system. Other key endpoints of the study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT), and other state-of-the-art invasive and non-invasive imaging modalities at six months, one year and two years.

Abbott's bioabsorbable drug eluting device delivers everolimus, a drug that inhibits tissue proliferation. The device props open and supports a narrowed blood vessel until the vessel heals, restoring blood flow, and is abs
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... results in demyelination, axonal transection, and neurodegeneration. The myelin ... the immune system, which targets neurons within the central ... in which the damage of the myelin sheath causes ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... TriReme Medical, Inc. (TMI) today announced approval by ... Glider™ PTCA Catheter, indicated for treating the stenotic portion ... perfusion. Glider™ is the world,s only torqueable ... art tip technology, Glider™ is designed to perform, even ...
... HAYWARD, Calif., and SHANGHAI, May 23, 2012 ... next-generation antibiotics, today announced that the U.S. Patent ... matter patent covering its clinical candidate, MRX-I. MRX-I ... due to multi-drug resistant Gram-positive pathogens. ...
Cached Medicine Technology:TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter 2MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent 2
(Date:9/1/2014)... Bioinformatics refers to an interdisciplinary ... and genetic data. A major part of this ... tools to generate and process useful biological data. ... computation. While bioinformatics simply makes use of computers ... related concepts, biological computation refers to the subfield ...
(Date:9/1/2014)... September 01, 2014 Ontraport , ... marketers that was developed to automate the small intricacies ... attention of Shane Michaels, prompting an investigative review. ... daily duty of managing all of the small details ... quite overwhelming,” reports Michaels. “That’s why Ontraport has become ...
(Date:9/1/2014)... California (PRWEB) September 01, 2014 Developers of ... new tutorial video for the ProWorld Plugin from Pixel Film ... Cut Pro X can do and users now have the ... images.” Said Christina Austin, CEO of Pixel Film Studios. “Blurring ... game changer.” , Learn how to turn a 2D HDRI ...
(Date:8/31/2014)... MYMOBILEUNI (MMU) strategy is to ... marketing tools access to digital, resources, courses, videos, ... all tools to reach and collaborate with educational ... learning channels. , MMU, today announced the availability ... tool that applies social networking concepts to the ...
(Date:8/31/2014)... Recently, BambooIndustry.com, one of the most popular suppliers ... selection of bamboo veneers . Additionally, it has deiced ... these high quality products. The promotion will last from today ... that its top quality veneers are hot in the global ... of bamboo veneers. All these items are made according to ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 3Health News:High Quality Bamboo Veneers from Bambooindustry.com Receive International Attention 2
... have an easier time breathing if they spend even ... air pollution, a study led by Giovanni Piedimonte, M.D., ... the West Virginia University School of Medicine, ... journal Pediatrics, shows for the first time that limiting ...
... study published today online in The Lancet ... for the bioabsorbable everolimus coronary stent. Commenting on ... from the University Hospital Zurich (Switzerland) and official ... , "In addition to the ABSORB study presenting ...
... "Extremely Affordable Health Innovations" Poster Session, organized and ... Congress with support from Grameen Health, will serve ... developing or implementing extremely affordable solutions in health ... and business processes they have developed, or are ...
... deliver something provocative." , "Listen to caregivers and be ... is coming; you can either master it or it ... nation sits on the cusp of massive health care ... a unique approach to leading the charge to control ...
... 13 Clinical Care Options (CCO), a leader in ... HIV information provider, have been named the official providers ... International AIDS Society Conference on HIV Pathogenesis, Treatment and ... 19-22, 2009, and the XVIII International AIDS Conference in ...
... Association (APDA) and the National Parkinson Foundation (NPF) Announce ... Conferences; First to be held in Dallas, Texas, October ... The American Parkinson Disease Association,s (APDA) National Young Onset ... Parkinson Network announced their first joint collaboration today. APDA ...
Cached Medicine News:Health News:City Kids May Breathe Easier in the Country 2Health News:Bioabsorbable stents show promise 2Health News:Extremely affordable health innovations at World Health Care Congress, April 14-16, Washington 2Health News:Extremely affordable health innovations at World Health Care Congress, April 14-16, Washington 3Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 2Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 3Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 4Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 2Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 3Health News:Young Onset Parkinson Conferences: A First-Ever Collaboration 2Health News:Young Onset Parkinson Conferences: A First-Ever Collaboration 3
... is a powerful, multi-modality system capable of performing ... EMG, EEG, and train of four testing tests ... a priority. The base weighs only 4.25 lbs. ... lbs. A desktop PC-based system with a custom ...
... Endeavor is a neuromonitoring system especially designed ... Endeavor amplifier has 16 channels and is ... electrode inputs. Each channel can be independently ... a true differential channel. Endeavor amplifiers are ...
... Inc. is the largest independently ... to ophthalmic surgical instrumentation. Katena ... 7,000 customers in the United ... network of distributors, to customers ...
... stress . . . Theyre all factors ... Unfortunately, its difficult, and often overwhelming, to ... daily basis. Its even more difficult to ... information to a care provider quickly so ...
Medicine Products: